Under the terms of the new deal, Hims & Hers will no longer sell compounded versions of semaglutide, a practice that has sparked lawsuits between the company and Novo Nordisk and against which the FDA recently launched a crackdown
Not for Diagnostic or Therapeutic Applications
Dissolving a known mass of peptide in a known volume of bacteriostatic water produces a known concentration, full stop
Healthcare practitioner channels, fitness centers, dermatology programs, longevity clinics, and e-commerce subscription platforms are accelerating market penetration, reinforcing the shift toward clean-label, clinically validated, and compliance-focused nutraceutical models
The mechanisms of this phenomenon remain unclear